Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.
about
Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition.Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life.Chronic Myeloid Leukemia-the Promise of Tyrosine Kinase Inhibitor Discontinuation.How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.Revisiting the need for bone marrow examination in chronic myeloid leukemia.Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells.Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making.Similar expression profiles in CD34+ cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib.A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea.Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes?Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey.First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysisThe transformative journey of chronic myeloid leukemia
P2860
Q47093658-36B25731-A7BB-46E3-B018-A530A8165122Q47727322-4DABF3FE-9923-4AF7-B4F7-7A353985A454Q47929120-51CD9245-82A2-47DE-A586-F9B33D7EEC14Q48162932-223D4A5B-82C9-4D58-9324-EC47A02A6A91Q48193546-71A27ABA-8C12-49F5-8186-157E53B4762DQ50422379-8B0D4CC1-7F5E-45B4-8C4C-8638629DD0E7Q52430614-E2D09595-1761-4DD7-911A-93FC1D526432Q52567954-867FFE38-5725-44BF-A350-C0D128910739Q52715772-F7451FD9-235F-4858-B3FB-E1F080E0BCC7Q53077187-0A0DA3BB-6B35-454B-94D5-51F9180B8A6BQ54977220-DF47CAF4-1AF5-4E43-8206-EE8C0C00B156Q55345383-46A4A84E-84FC-40F0-8A53-AB7A85C7F5D7Q57069646-B6C54D8A-D2B6-4634-B47F-0EE37D25DC0DQ57300926-E28BFD9D-4A12-4DFE-A768-E848A612FA81
P2860
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.
description
2017 nî lūn-bûn
@nan
2017 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Treatment-free remission follo ...... s from the ENESTfreedom study.
@ast
Treatment-free remission follo ...... s from the ENESTfreedom study.
@en
type
label
Treatment-free remission follo ...... s from the ENESTfreedom study.
@ast
Treatment-free remission follo ...... s from the ENESTfreedom study.
@en
prefLabel
Treatment-free remission follo ...... s from the ENESTfreedom study.
@ast
Treatment-free remission follo ...... s from the ENESTfreedom study.
@en
P2093
P2860
P50
P356
P1433
P1476
Treatment-free remission follo ...... s from the ENESTfreedom study.
@en
P2093
A Hellmann
A Hochhaus
E Conneally
H D Menssen
J P Radich
J Stentoft
N Gattermann
P2860
P2888
P304
P356
10.1038/LEU.2017.63
P577
2017-02-20T00:00:00Z
P6179
1083850241